Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis
By S. Chu, Richard C. Becker, P. Berger, Deepak L. Bhatt, J. Eikelboom, B. Konkle, E. Mohler, M. Reilly, J. Berger. Journal of Thrombosis and Haemostasis, 2009
1,065 citations recorded by the source corpus.
See also Machin SJ, Briggs C. Mean platelet volume: a quick, easy determinant of thrombotic risk? This issue, pp 146–7.
Subfields: Cardiology and Cardiovascular Medicine, Oncology, Statistics and Probability
View Paper: https://www.semanticscholar.org/paper/e530296c825fda15bd79929325ac807a4244d077
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Statistics and Probability
- Shenmin Zhang
- Sara A. van de Geer
- Peter Buhlmann
- Jelena Bradic
- Mladen Kolar
- Victor Chernozhukov
- Jana Jankov'a
- Jonathan E. Taylor
Citations in the corpus
- SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19 (2020, background): “MPV was shown to correlate with platelet activity and is considered a marker of platelet activity [49, 50]; therefore, increased MPV in COVID-19 suggests that these platelets may present as hyperactive.”
- The incredible journey: From megakaryocyte development to platelet formation (2013, background): “…(mean platelet volume) is associated with increased platelet aggregation, increased expression of adhesion molecules, and elevated risk of cardiovascular and peripheral arterial diseases (Bath and Butterworth, 1996; Kamath et al., 2001; Berger et al., 2010; Chu et al., 2010; Slavka et al., 2011).”